WARNER-LAMBERT COGNEX NEW SCRIPTS ARE 50,000 FOR MARCH, TACRINE ON 87% OF FORMULARIES; COMPANY RESTRUCTURING SALES INTO CBUs IN LIGHT OF MANAGED CARE
Executive Summary
New prescriptions for Warner-Lambert's Alzheimer's treatment Cognex (tacrine) were approximately 50,000 for the month of March, Parke-Davis North America President Harold Oberkfell told securities analysts at an April 15 meeting in New York City.